Drug prices in several disease areas outpace other healthcare expenditures and result in inadequate availability of essential medicines globally, according to a recently published review.
The cost of the cancer drug Gleevec tripled after the FDA approved a new indication, the $1000-per-pill hepatitis C virus (HCV) treatment Sovaldi accounted for 64% of US HCV-related spending in 2014, and the cost of the 60-year-old drug Daraprim went from $13.50 per pill to $750 per pill after Turing Pharmaceuticals acquired its distribution license. Reports like these led to hearings in the US Congress examining the pricing practices of pharmaceutical companies. In the United Kingdom, costly cancer immunotherapies faced rejection for National Health Service coverage reimbursement, and the German government is planning to curb pharmaceutical companies’ right to set launch prices. The sharply rising prices of prescription medications even became an issue in the 2016 US presidential election.
Drug prices in several disease areas outpace other healthcare expenditures and result in inadequate availability of essential medicines globally, according to a review by Toon van der Gronde, PharmD, and colleagues in a recent issue of PLOS One. They note that high prices for medicines, however innovative, are untenable and often beyond the ability of individuals, health insurance companies, or even governments in high-income countries to pay. Health systems therefore face a challenge in striking a balance between rewarding investments in innovation, achieving reasonable drug prices, and securing equitable access to medicines—a challenge that demands new policies to prevent a continued drug pricing spiral, van der Gronde and colleagues conclude.
The investigators searched PubMed for peer-reviewed English-language scientific articles on drugs and cost as well as reputable news outlets such as the Financial Times, The New York Times, the Wall Street Journal, and The Guardian for articles concerning the pricing of medicines between January 2014 and January 2017. Their review first examines the concepts of drug life-cycle dynamics, government interventions aimed at reducing drug prices, and the consequences of those interventions, and then suggests alternative policy measures to reduce drug prices and improve access to innovative and essential medications.
Van der Gronde and colleagues argue that fertile ground for high-priced drugs was created by several factors:
Van der Gronde and colleagues recommend the following steps to reduce drug prices:
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.